PHILADELPHIA – When given a choice, most individuals with an average risk of colorectal cancer said they would prefer a stool-based screening test for colorectal cancer over colonoscopy, the method most often recommended by health care providers, according to results published in Although colorectal cancer is the second most frequent cause of cancer-related death in the United States, about one-third of eligible American adults have never completed a colorectal cancer screening test, explained lead author Xuan Zhu, PhD, senior health services analyst at the Mayo Clinic Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery. Zhu added that colorectal cancer screening is particularly underutilized by individuals experiencing socioeconomic disadvantages, racial and ethnic minorities, and certain age groups.
E-Mail
Bottom Line: When given a choice, most individuals with an average risk of colorectal cancer said they would prefer a stool-based screening test for colorectal cancer over colonoscopy, the method most often recommended by health care providers.
Journal in Which the Study was Published:
Cancer Prevention Research, a journal of the American Association for Cancer Research
Author: Xuan Zhu, PhD, senior health services analyst at the Mayo Clinic Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery
Background: Although colorectal cancer is the second most frequent cause of cancer-related death in the United States, about one-third of eligible American adults have never completed a colorectal cancer screening test, explained lead author Zhu. Zhu added that colorectal cancer screening is particularly underutilized by individuals experiencing socioeconomic disadvantages, racial and ethnic minorities, and certain age groups.
Five Clinical Highlights From AACR Annual Meeting (Part 1) medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
Onxeo Reports Full-Year 2020 Financial Results and Provides Business Update
> Several major clinical milestones achieved in 2020 by AsiDNA, including promising initial results in combination with chemotherapy and the launch of a new study to evaluate the abrogation of resistance to a targeted therapy
> Cash position of €14.5 million at December 31, 2020 supplemented by €14.7 million in new financing obtained in early 2021
> Extended financial visibility through the end of 2022, enabling the expansion of clinical and industrial development of AsiDNA
Regulatory News:
https://us02web.zoom.us/webinar/register/WN T6v8Hc8TRU67rKXPrz2nXw
Onxeo S.A. (Euronext Growth Paris: ALONX, Nasdaq First North Copenhagen: ONXEO) (Paris:ALONX) (NASDAQ OMX:ALONX), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage response (DDR) in oncology, today reported its consolidated financial results for the fiscal ending December 31,
Unusual Treatment Shows Promise for Kids With Brain Tumors
3 hours ago
This 2016 photo provided by the family shows Jake Kestler, center, with his parents, Gallite and Josh, and his sister, Lily. This is one month before he was diagnosed with brain cancer. (Family Photo via AP)
Share
share
The URL has been copied to your clipboard
0:00
0:06:54
0:00
From VOA Learning English, this is the Health & Lifestyle report.
For many years, a deadly type of childhood cancer has escaped science’s best treatments. But now doctors have made progress with an unusual treatment. They inject a virus into the brain to infect the